Compare Abeona Therapeutics Inc (ABEO) vs American Tower Corp (AMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs American Tower Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while American Tower Corp trades at $164.49 (market cap $76.99B). The key difference: American Tower Corp is far larger — about 206.2× Abeona Therapeutics Inc's market cap, and American Tower Corp pays a 4.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AMT | |
|---|---|---|
Market Cap | $373.32M | $76.99B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $232.35 |
52-Week Low | $4.17 | $162.11 |
Enterprise Value | $228.22M | $120.51B |
Dividend Yield | — | 4.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMT trades at $165.25, down 0.47% on the day, with a bearish technical signal from moving averages and oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Strong profitability is evident with a net margin of 26.81% and ROE of 82.19%, though valuation ratios like P/E of 26.15 and P/B of 21.44 appear elevated. Recent news highlights steady revenue growth and sustainability initiatives.
The outlook remains positive with a consensus price target of $217, implying significant upside, supported by 38 buy ratings and no sell recommendations. Risks include high debt levels and competitive pressures from satellite technology. The stock offers a solid dividend yield, with the next payment scheduled for July 13, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →
